STAT September 3, 2020
Nicholas Florko

WASHINGTON — A group of prominent biotech CEOs are calling on their peers and the federal government to hold themselves to the highest standards when it comes to developing and reviewing Covid-19 treatments.

Among their demands: That biotech companies don’t simply release clinical trial data in press releases, and that federal regulators make it clear to the public that any vaccines or treatments will be approved strictly based on science.

The recommendations were laid out in an open letter organized by the Biotechnology Innovation Organization and published Thursday. The letter comes amid growing concern among the American public over the politicization of the Covid-19 pandemic. A new poll conducted by STAT and Harris Poll found that nearly 80% of Americans...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
It's Not Just Congress. There's Plenty of State-Level Action on PBMs, Drug Costs and Prices | AMCP 2024
Cullinan Nets $280M Investment and Targets CD19 in Lupus
Eli Lilly Shows Obesity Drug Zepbound Can Treat Sleep Apnea Too
On the Front Lines: Pharmacists' Role in Combating America's Opioid Epidemic
Fierce Biotech Layoff Tracker 2024: Ultimovacs says goodbye to 40% of staff; Major pharmas turn to layoffs

Share This Article